Marquette Asset Management LLC Reduces Stake in Chimerix, Inc. (NASDAQ:CMRX)

Marquette Asset Management LLC lowered its position in Chimerix, Inc. (NASDAQ:CMRX) by 6.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 108,986 shares of the biopharmaceutical company’s stock after selling 7,023 shares during the period. Marquette Asset Management LLC owned about 0.12% of Chimerix worth $379,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of Chimerix during the 2nd quarter valued at about $137,000. Valeo Financial Advisors LLC boosted its holdings in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 69,505 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 138,098 shares during the period. Finally, Assenagon Asset Management S.A. increased its holdings in Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after buying an additional 496,823 shares during the last quarter. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Trading Up 1.8 %

NASDAQ CMRX opened at $3.37 on Wednesday. The stock has a market cap of $303.08 million, a price-to-earnings ratio of -3.59 and a beta of 0.36. Chimerix, Inc. has a 12 month low of $0.75 and a 12 month high of $3.80. The company’s 50 day moving average is $2.11 and its two-hundred day moving average is $1.32.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CMRX shares. Wedbush reissued an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Chimerix in a research report on Monday, December 30th.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.